^
Association details:
| Biomarker: | ALK fusion + FAT3 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | foritinib (SAF-189) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1364P - ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
Published date:
10/16/2023
Excerpt:
...a total of 143 NSCLC ALK-fusion positive pts had been enrolled and treated with SAF-189s…Gene co-occurrence survival analysis showed that mPFS of pts harboring FAT3/FAT4 mutations were significantly shorter than those without FAT3/FAT4 mutations (8.9 mo vs 16.5 mo, p=0.012).
Trial ID:
